CN102552301A - Medicine composition and application thereof - Google Patents
Medicine composition and application thereof Download PDFInfo
- Publication number
- CN102552301A CN102552301A CN2011104623281A CN201110462328A CN102552301A CN 102552301 A CN102552301 A CN 102552301A CN 2011104623281 A CN2011104623281 A CN 2011104623281A CN 201110462328 A CN201110462328 A CN 201110462328A CN 102552301 A CN102552301 A CN 102552301A
- Authority
- CN
- China
- Prior art keywords
- luteolin
- physalin
- nitric oxide
- luteoloside
- glucopyranoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a synergistic effect of medicine composition of physalin A and luteoloside or luteolin-7-O-beta-D-glucopyranoside) or luteolin in inhibiting in vitro activity of rat RAW 264.7 macrophage releasing nitric oxide (NO) induced by lipopolysaccharide and a novel application in the medical field. The invention finds the synergistic effect of physalin A and luteoloside (or luteolin-7-O-beta-D-glucopyranoside) or luteolin in inhibiting NO release, which provides scientific evidence of traditional application of traditional Chinese medicine wintercherry in clearing heat and detoxicating as well as relieving sore throat and reducing phlegm. The composition of the physalin A and luteoloside (or luteolin-7-O-beta-D-glucopyranoside) or luteolin can be used for treating the diseases, such as cancer, inflammation, immune and the like relevant to pathogenesis and metabolic disorder of nitric oxide.
Description
Technical field
The present invention relates to medical technical field; Relate to a kind of pharmaceutical composition and application thereof; Definite says so; Physalin A and Luteolin (or luteolin) suppress the synergism that LPS induces RAW 264.7 cells generation nitric oxide (NO), and the two controls the new purposes of Chinese medicine Calyx Seu Fructus Physalis (Calyx seu fructus physalis) quality aspect at the same time.
Background technology
Nitric oxide (NO) is a kind of novel cell messenger molecule of discovered in recent years; Its mediation and regulate the multiple physiology comprise inflammation and pathological process (Chen Minzhu. nitric oxide and inflammation immunocyte. Chinese Pharmacological is circulated a notice of; 1992,8,409-415.); In inflammation, immunity, cancer, play important biological action in the processes such as cardiovascular and cerebrovascular vessel adjusting.In vivo, NO is formed by the catalytic oxidation of arginine guanidine radicals nitrogen process nitric oxide synthetase (NOS), and wherein the expression of induced NOS (iNOS) and inflammation and tumor are closely related.When macrophage receives the stimulation of lipopolysaccharide (LPS), interferon (IFN) etc., can activate the expression of iNOS mRNA, translate into iNOS again, and then a large amount of NO of catalysis generation, performance kills and wounds the effect of pathogenic microorganism and tumor cell.But then, the NO that is produced by iNOS catalysis discharges too much, can the non-selective damage that causes cell and tissue, and the initiation various diseases is like the exacerbate inflammation reaction etc.Recent study shows that NO is relevant with the hypertrophy of canceration and cancerous tissue; The NO meeting modificator gene sudden change of high concentration and tumor (hide the dream dimension, Liu Jingsheng. nitric oxide production mutagenicity and carcinogenecity. foreign medical science physiology, pathology science and clinical fascicle, 1998; 18 (1), 37-40.).In addition, the NO Developmental and Metabolic Disorder can also cause the generation of serious diseases such as asthma, apoplexy, acute myeloid leukaemia, Parkinson's disease, presenile dementia.
The Calyx seu fructus physalis beginning is stated from Shennong's Herbal; Has heat clearing away and restlessness relieving; The effect of pharynx-clearing throat-benefiting; Thereafter book on Chinese herbal medicine has collection more the successive dynasties, and each edition of the Pharmacopoeia of the People's Republic of China all recorded the Constellation calyx of dry Constellation calyx or band fruit of P.alkekengi L.var.francheti (Calyx seu fructus physalis) as medicinal, another name " Calyx Seu Fructus Physalis ".Be used to treat the pharyngalgia hoarseness, phlegm-heat cough, dysuria; The external treatment pemphigus, and eczema (Chinese Pharmacopoeia Commission. Pharmacopoeia of People's Republic of China: an one [Z]. Beijing: Chemical Industry Press, 2010.337-338).Physalin class steroidal lactone and flavone compound are two big types of main active in the Calyx Seu Fructus Physalis; Have effect (Li-Xia Chen such as anticancer, antiinflammatory, immunomodulating; Hao He, Feng Qiu.Natural withanolides:nn overview.Natural Product Reports, 2011; 28 (4), 705-740.).Though this seminar induces the external activity aspect of RAW 264.7 cells generation NO to carry out studying (Li Qiu, Feng Zhao, ZhiHu Jiang to physalin and flavones ingredient inhibition LPS early stage; LiXia Chen; Qian Zhao, HongXia Liu, XinSheng Yao; Feng Qiu.Steroids and Flavonoids from Physalis alkekengi var.franchetii and Their Inhibitory Effects on Nitric Oxide Production.Journal of Natural Products; 2008,71 (4), 642-646; Li Qiu, Zhi-Hu Jiang, Hong-Xia Liu; Li-Xia Chen, Xin-Sheng Yao, Feng Qiu.A pair of 3-epimeric physalins from Physalis alkekengi L.var.franchetii; Journal of Asian Natural Product Research; 2008,10 (9), 881-885; Qiu Li, Jiang Zhihu, Liu Hongxia, Chen Lixia, Qu Gexia, Qiu Feng. the flavonoid glycoside compound of Calyx Physalis, Shenyang Pharmaceutical University's journal, 2007,24 (12), 744-747; Qiu Li. chemical Constituents from Physalis alkekengi and bioactivity research thereof, Shenyang Pharmaceutical University's doctorate paper, 2008 .), but also do not see any document and patent report for the synergism research that two constituents inhibition NO produces.
Summary of the invention
The present invention uses external activity screening system to carry out activity rating; Find that physalin A and Luteolin (or luteolin) have the synergism that suppresses RAW 264.7 cells generation NO; Show that these two compound compositions possibly have the disease that treatment causes owing to the NO Developmental and Metabolic Disorder; Like inflammation, cancer, asthma, apoplexy, presenile dementia etc.; Be that index components can be carried out quality control to Chinese medicine Calyx Seu Fructus Physalis and extract thereof and preparation simultaneously, have good research and development prospect with physalin A and Luteolin.
Primary and foremost purpose of the present invention is to provide the drug regimen treatment pathogenesis and the related various diseases of nitric oxide production Developmental and Metabolic Disorder of physalin A and Luteolin (luteolin).
Physalin A of the present invention and Luteolin or luteolin are in this seminar early-stage Study and from the Calyx Seu Fructus Physalis medical material, prepare purity＞98%.
Another object of the present invention is to provide and adopt physalin A and two active ingredient of Luteolin simultaneously, the method for control Calyx Seu Fructus Physalis medical material and the extract and the quality of the pharmaceutical preparations as index.
Range of application of the present invention comprises various because the disease that the NO Developmental and Metabolic Disorder is caused.
At first; Physalin A and Luteolin Combined application can be used for treating the disease that the NO Developmental and Metabolic Disorder is caused; Comprising but be not limited to; Systemic inflammatory response syndrome, hypertension, cerebral thrombosis, heart failure, liver cirrhosis, rheumatoid arthritis, osteoarthritis, scorching, the inflammatory bowel of joint of vertebral column, acute pancreatitis, peritonitis, cholecystitis, appendicitis, diabetes, systemic lupus erythematosus (sle), dermatomyositis, psoriasis, acute myeloid leukaemia, Parkinson's disease, presenile dementia, depression, septicemia, chronic obstructive pulmonary disease, asthma, acute pancreatitis, central nervous system injury etc.
Secondly, the NO Developmental and Metabolic Disorder is also relevant with the hypertrophy of canceration and cancerous tissue, and the NO of high concentration also can suddenly change and tumor by modificator gene, and physalin A and Luteolin Combined application can produce synergism, and suppress NO and discharge, thus the performance antineoplastic action.The tumor example that is suitable for includes but not limited to: various entity tumors and leukemia, and like pulmonary carcinoma, hepatocarcinoma, cancer of pancreas, gastric cancer, osteocarcinoma, esophageal carcinoma, carcinoma of prostate, colon cancer, ovarian cancer, bladder cancer, cervical cancer, melanoma, carcinoma of testis, bronchogenic carcinoma, renal cell carcinoma, cancer of biliary duct, choriocarcinoma, glioma, neurofibroma, fibrosarcoma, lymphangioma etc.
The invention provides the pharmaceutical composition that physalin A and Luteolin are combined to form; Its weight mixed proportion is any number in effective dosage ranges; Preferable ratio is 1: 50～50: 1 (weight ratio), and better ratio is 1: 10～10: 1 (weight ratio).Said composition can be processed various conventional formulations and dosage form with available various adjuvants on the pharmacy meaning; Adopt oral, parenteral (for example; Intramuscular, intraperitoneal, intravenous, intracisternal injection or infusion, subcutaneous injection or implantation; Or through sucking spray, or per nasal, vagina, rectum, Sublingual or topical approach) mode of administration, be used for prevention and treat various and NO Developmental and Metabolic Disorder diseases associated.
Because Luteolin belongs to the flavonoid glycoside composition; Oral back is prone to change into luteolin in gastrointestinal tract; The main in vivo form with its aglycon luteolin is absorbed into blood and plays a role; Therefore we have also studied the effect situation of physalin A and luteolin compositions, and the result shows to have similar synergism.
The relative prior art of the present invention has following advantage and effect:
Physalin A and Luteolin (or luteolin) drug combination performance synergism is provided, has treated various because the disease that the NO Developmental and Metabolic Disorder is caused.The monomer component that compositions relates to derives from natural material, has safe and reliable characteristics.
Description of drawings
Fig. 1 is the high-efficient liquid phase chromatogram (retention time is 12.57min) of Luteolin;
Chromatographic condition: chromatographic column: Aglient ZORBAX SB-C18 (4.6 * 150mm) 5 μ m
Detect wavelength: 350nm
Flow velocity: 1.0mL/min
Column temperature: 30 ℃
Sample size: 10 μ L (0.2mg/mL)
Mobile phase: A (acetonitrile), B (0.2% phosphoric acid-water)
0-10min(10％A→20％A)；10-25min(20％A→35％A)；25-30min
(35％A)；30-35min(100％A)；35-40min(10％A)
Fig. 2 is the high-efficient liquid phase chromatogram (retention time is 21.35min) of luteolin;
Chromatographic condition: chromatographic column: Agliem ZORBAX SB-C18 (4.6 * 150mm) 5 μ m
Detect wavelength: 350nm
Flow velocity: 1.0mL/min
Column temperature: 30 ℃
Sample size: 10 μ L (0.2mg/mL)
Mobile phase: A (acetonitrile), B (0.2% phosphoric acid-water)
0-10min(10％A→20％A)；10-25min(20％A→35％A)；25-30min
(35％A)；30-35min(100％A)；35-40min(10％A)
Fig. 3 is the high-efficient liquid phase chromatogram (retention time is 26.02min) of physalin A;
Chromatographic condition: chromatographic column: Aglient ZORBAX SB-C18 (4.6 * 150mm) 5 μ m
Detect wavelength: 220nm
Flow velocity: 1.0mL/min
Column temperature: 30 ℃
Sample size: 10 μ L (0.2mg/mL)
Mobile phase: A (acetonitrile), B (0.2% phosphoric acid-water)
0-10min(10％A→20％A)；10-25min(20％A→35％A)；25-30min(35％A)；
30-35min(100％A)；35-40min(10％A)
The specific embodiment
The present invention can explain through following embodiment.
Embodiment 1: Luteolin and physalin A drug combination discharge the inhibition activity experiment of nitric oxide (NO) to lipopolysaccharide-induced mouse monokaryon macrophage RAW 264.7
Mouse monokaryon macrophage RAW 264.7 (ATCC TIB-71) is incubated at and contains (56 ℃ of 10% hot deactivations; 30min) in RPMI 1640 (Gibco) culture fluid of hyclone (FBS), 100U/mL penicillin sodium (Gibco), 100 μ g/mL streptomycins (Gibco); 37 ℃, 5%CO
2Constant incubator in hatch growth.
Because NO is extremely unstable, in cell culture supernatant, is metabolized to nitrito-(NO very soon
2 -), so adopt NO in the Griess method working sample
2 -Concentration as the index of weighing the NO level.The Griess reagent A: (naphthylethylene diamine dihydrochloride) is soluble in water for 0.1%N-naphthodiamide hydrochlorate; Griess reagent B:1% P-aminobenzene-sulfonamide (sulphanilamide) is dissolved in 5%H
3PO
4In.Equal-volume mix reagent A and B before using.
With the RPMI RPMI-1640 with RAW 264.7 cell dilutions to 5 * 10
5Cells/mL concentration is inoculated in the 96 porocyte culture plates, and every hole adds 200 μ L cell suspending liquids.CO
2After cultivating 1h in the incubator, every hole adds lipopolysaccharide (lipopolysaccharide, the specimen 0.4 μ L of LPS) (Sigma) (final concentration 1 μ g/mL) and the dissolved variable concentrations of DMSO; Establish the LPS group simultaneously and (add LPS; But do not add specimen, the suppression ratio that NO is discharged is 0%) and the blank group (do not add LPS and specimen, only add 0.4 μ LDMSO; The suppression ratio that NO is discharged is 100%), each sample is established 4 parallel holes.At 37 ℃, 5%CO
2Cultivate 24h in the constant incubator, draw 100 μ L culture fluid supernatants to ELISA Plate, centrifugal (1000 * g, 3min), adds 100 μ L Griess reagent, room temperature lucifuge reaction 10min, the light absorption value in its 540nm place of ELIASA mensuration by 4 ℃.Be respectively the NaNO of 1,5,10,50 μ mol/L with concentration
2The drawing standard curve is according to NaNO
2Standard curve calculates NO in the cell culture supernatant
2 -Concentration so that calculate the suppression ratio that specimen discharges NO.
Experimental result is following:
Physalin A (0.78125 μ mol/L) medication separately is 36.5 ± 9.1% to the suppression ratio that LPS induces RAW 264.7 cells to produce NO.Luteolin and physalin A drug combination 24 hours have synergism (Q＞1.15).
The Luteolin of table 1 variable concentrations and physalin A cooperate with the result (%) of RAW 264.7 cells
Annotate: calculate Q-value and judge the joint effect of two medicines by following formula: Q=E (A+B)/(EA+EB-EA * EB), wherein E (A+B) is the suppression ratio that two medicines share, and EA and EB are respectively the suppression ratio that two prescriptions are used.Q is 0.85～1.15 expression, two medicine effect additions, and Q＞1.15 expressions, two medicine effects are collaborative, Q＜0.85 expression, two medicine effect antagonisms.
Embodiment 2: physalin A and Luteolin drug combination discharge the inhibition activity experiment of nitric oxide (NO) to lipopolysaccharide-induced mouse monokaryon macrophage RAW 264.7
Activity test method suppresses the NO release experiment with Luteolin and physalin A drug combination.
Experimental result is following:
Luteolin (0.78125 μ mol/L) medication separately is 3.7 ± 7.5% to the suppression ratio that LPS induces RAW 264.7 cells to produce NO.Physalin A and Luteolin drug combination 24 hours have synergism (Q＞1.15).
The Luteolin of table 2 variable concentrations and physalin A cooperate with the result (%) of RAW 264.7 cells
Annotate: calculate Q-value and judge the joint effect of two medicines by following formula: Q=E (A+B)/(EA+EB-EA * EB), wherein E (A+B) is the suppression ratio that two medicines share, and EA and EB are respectively the suppression ratio that two prescriptions are used.Q is 0.85～1.15 expression, two medicine effect additions, and Q＞1.15 expressions, two medicine effects are collaborative, Q＜0.85 expression, two medicine effect antagonisms.
Embodiment 3: luteolin and physalin A drug combination discharge the inhibition activity experiment of nitric oxide (NO) to lipopolysaccharide-induced mouse monokaryon macrophage RAW 264.7
Activity test method suppresses the NO release experiment with Luteolin and physalin A drug combination.
Experimental result is following:
Physalin A (0.78125 μ mol/L) medication separately is 36.5 ± 9.1% to the suppression ratio that LPS induces RAW 264.7 cells to produce NO.Luteolin and physalin A drug combination 24 hours have synergism (Q＞1.15)
The luteolin of table 3 variable concentrations and physalin A cooperate with the result (%) of RAW 264.7 cells
Annotate: calculate Q-value and judge the joint effect of two medicines by following formula: Q=E (A+B)/(EA+EB-EA * EB), wherein E (A+B) is the suppression ratio that two medicines share, and EA and EB are respectively the suppression ratio that two prescriptions are used.Q is 0.85～1.15 expression, two medicine effect additions, and effect is collaborative approximately in Q＞1.15 expressions two, Q＜0.85 expression, two medicine effect antagonisms.
Embodiment 4: physalin A and luteolin drug combination discharge the inhibition activity experiment of nitric oxide (NO) to lipopolysaccharide-induced mouse monokaryon macrophage RAW 264.7
Activity test method suppresses the NO release experiment with Luteolin and physalin A drug combination.
Experimental result is following:
Luteolin (0.39063 μ mol/L) medication separately is 10.3 ± 2.4% to the suppression ratio that LPS induces RAW 264.7 cells to produce NO.Physalin A and luteolin drug combination 24 hours have synergism (Q＞1.15)
The luteolin of table 4 variable concentrations and physalin A cooperate with the result (%) of RAW 264.7 cells
Annotate: calculate Q-value and judge the joint effect of two medicines by following formula: Q=E (A+B)/(EA+EB-EA * EB), wherein E (A+B) is the suppression ratio that two medicines share, and EA and EB are respectively the suppression ratio that two prescriptions are used.Q is 0.85～1.15 expression, two medicine effect additions, and effect is collaborative approximately in Q＞1.15 expressions two, Q＜0.85 expression, two medicine effect antagonisms.
Embodiment 5: the preparation of pharmaceutical composition physalin A of the present invention and Luteolin tablet
1. write out a prescription:
Prescription 1:
Prescription 2:
Prescription 3:
2. preparation technology: raw material, adjuvant are crossed 100 mesh sieves respectively, subsequent use; Take by weighing raw material and adjuvant according to recipe quantity; With compositions, microcrystalline Cellulose, the pregelatinized Starch of physalin A and Luteolin, mix homogeneously, it is an amount of to add water, stirs, and processes suitable soft material; Cross 20 mesh sieve system granules; Granule is dried under 60 ℃ of conditions; Dry good granule adds magnesium stearate and carboxymethylstach sodium, crosses 18 mesh sieve granulate, mix homogeneously; Tabletting.
Embodiment 6: the preparation of pharmaceutical composition physalin A of the present invention and Luteolin aqueous injection
1. write out a prescription:
Prescription 1:
Prescription 2:
Prescription 3:
2. preparation technology: with compositions, tween 80, the water for injection dissolving dosing of physalin A and Luteolin, handle after-filtration, standardize solution, fine straining, embedding, sterilization, leak detection, lamp inspection through activated carbon adsorption, after process the aqueous injection finished product.
Embodiment 8: the preparation of pharmaceutical composition physalin A of the present invention and luteolin tablet
1. write out a prescription:
Prescription 1:
Prescription 2:
Prescription 3:
2. preparation technology: raw material, adjuvant are crossed 100 mesh sieves respectively, subsequent use; Take by weighing raw material and adjuvant according to recipe quantity; With compositions, microcrystalline Cellulose, the pregelatinized Starch of physalin A and luteolin, mix homogeneously, it is an amount of to add water, stirs, and processes suitable soft material; Cross 20 mesh sieve system granules; Granule is dried under 60 ℃ of conditions; Dry good granule adds magnesium stearate and carboxymethylstach sodium, crosses 18 mesh sieve granulate, mix homogeneously; Tabletting.
Embodiment 7: the preparation of pharmaceutical composition physalin A of the present invention and luteolin aqueous injection
1. write out a prescription:
Prescription 1:
Prescription 2:
Prescription 3:
2. preparation technology: with compositions, tween 80, the water for injection dissolving dosing of physalin A and Luteolin, handle after-filtration, standardize solution, fine straining, embedding, sterilization, leak detection, lamp inspection through activated carbon adsorption, after process the aqueous injection finished product.
Claims (5)
1. a pharmaceutical composition is characterized in that, contains two components of physalin A and Luteolin.
2. pharmaceutical composition as claimed in claim 1 is characterized in that described Luteolin is replaced by luteolin.
3. according to claim 1 or claim 2 pharmaceutical composition, it is characterized in that physalin A: Luteolin or physalin A: the weight ratio of luteolin is 1: 50～50: 1.
4. according to claim 1 or claim 2 pharmaceutical composition, it is characterized in that physalin A: Luteolin or physalin A: the weight ratio of luteolin is 1: 20～8: 1.
5. claim 1 or the 2 described pharmaceutical compositions application in the medicine of preparation treatment and the related disease of nitric oxide production Developmental and Metabolic Disorder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110462328.1A CN102552301B (en) | 2011-12-31 | 2011-12-31 | Medicine composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110462328.1A CN102552301B (en) | 2011-12-31 | 2011-12-31 | Medicine composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102552301A true CN102552301A (en) | 2012-07-11 |
| CN102552301B CN102552301B (en) | 2014-04-02 |
Family
ID=46399760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110462328.1A Active CN102552301B (en) | 2011-12-31 | 2011-12-31 | Medicine composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102552301B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103214497A (en) * | 2013-04-15 | 2013-07-24 | 沈阳药科大学 | Physalin A extracting process and medical application thereof |
| CN103263530A (en) * | 2013-05-23 | 2013-08-28 | 张文志 | Throat swelling-decreasing and pain-relieving granule and preparation method thereof |
| WO2016110269A1 (en) * | 2015-01-08 | 2016-07-14 | Tseng Wei-Kung | Antiplatelte agent and uses thereof |
| CN109776565A (en) * | 2019-01-28 | 2019-05-21 | 浙江省中医药研究院 | A kind of bitter taste chlorins compound and the preparation method and application thereof |
-
2011
- 2011-12-31 CN CN201110462328.1A patent/CN102552301B/en active Active
Non-Patent Citations (4)
| Title |
|---|
| LI QIU等: "Steroids and Flavonoids from Physalis alkekengi var. franchetii and Their Inhibitory Effects on Nitric Oxide Production", 《JOURNAL OF NATURAL PRODUCTS》 * |
| XU DAN等: "酸浆化学成分的研究", 《中草药》 * |
| 施蕊等: "R P 一H P L C 测定酸浆药材中3 种有效成分的含量", 《药物分析杂志》 * |
| 林峰等: "锦灯笼中酸浆苦素类化学成分的研究", 《现代药物与临床》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103214497A (en) * | 2013-04-15 | 2013-07-24 | 沈阳药科大学 | Physalin A extracting process and medical application thereof |
| CN103214497B (en) * | 2013-04-15 | 2015-08-12 | 沈阳药科大学 | Physalin A extraction process and medicinal use |
| CN103263530A (en) * | 2013-05-23 | 2013-08-28 | 张文志 | Throat swelling-decreasing and pain-relieving granule and preparation method thereof |
| WO2016110269A1 (en) * | 2015-01-08 | 2016-07-14 | Tseng Wei-Kung | Antiplatelte agent and uses thereof |
| CN109776565A (en) * | 2019-01-28 | 2019-05-21 | 浙江省中医药研究院 | A kind of bitter taste chlorins compound and the preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102552301B (en) | 2014-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103242275B (en) | Sesquiterpenoids in zedoary as well as preparation method and application of sesquiterpenoids | |
| CN102145159B (en) | Ginger and elecampane composition, preparation method of ginger and elecampane composition and use of ginger and elecampane composition for preparing toxicity-reducing efficacy-improving medicine in cancer radiotherapy and chemotherapy | |
| CN102552301B (en) | Medicine composition and application thereof | |
| CN102091314B (en) | Composition of dried ginger and evodia rutaecarpa, preparation method thereof and application thereof in preparing attenuating synergistic medicament in radiotherapy and chemotherapy of cancer | |
| CN104622865A (en) | Application of ingenane diterpene compound in preparation of antitumor drug | |
| CN105982871B (en) | A kind of Fructus Forsythiae aglycon tablet | |
| CN103263450A (en) | Traditional Chinese medicine compositio | |
| CN102614156A (en) | Medical application of in-vivo metabolite of paeonol | |
| CN102526667B (en) | Loquat leaf/ginger composition for reducing vomiting due to cancer chemotherapy and enhancing effect of cancer chemotherapy, and preparation method thereof | |
| CN105949266B (en) | Withanolide class compound and extracting method and application | |
| CN103893412B (en) | A kind of antitumor beautyberry extract and its production and use | |
| CN101152193B (en) | Application of 1,3,4-3-O-gallnut acyl-6-O-coffee acyl-beta-D-glucopyranose in preparing antineoplastic medicament | |
| CN106008641B (en) | Withanolide class compound and extracting method and purposes | |
| CN105949272B (en) | Wityaphysalin Y and extracting method and purposes | |
| CN103520661A (en) | Traditional Chinese medicinal enteric-coated tablets for treating proctitis, colitis and irritable bowel syndrome, as well as preparation method and application thereof | |
| CN101367802B (en) | Beta-kabarin alkaloids in quassia wood, preparation method and application thereof | |
| CN101569654A (en) | Supercritical extract of pigeon pea leaves and application of pigeon pea stilbene acid in the preparation of antitumor drug | |
| CN104173402B (en) | The preparation method and its anticancer purpose of general flavone in a kind of Inula britannica chinensis medicinal material | |
| CN107362158B (en) | Application of loganin aglycone in preparation of antitumor drugs | |
| CN104189249A (en) | Musk haemorrhoid suppository and preparation method thereof | |
| CN102335180A (en) | Application of ursane compounds in preparing antitumor drugs | |
| CN103263475A (en) | Traditional chinese medicine composition | |
| CN102166337A (en) | Ginger and inula flower composition as well as preparation method and application thereof in preparation of toxicity reducing and efficacy enhancing medicament in radiotherapy and chemotherapy of cancer | |
| CN106045821A (en) | A preparing method for a cortex magnoliae officinalis phenol and an antitumor application of the phenol | |
| CN105477068A (en) | Preparation method and application of active parts of mulberry branch leaves |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |